Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin

Details for Australian Patent Application No. 2004257781 (hide)

Owner Schering Corporation

Inventors Oft, Martin

Agent Griffith Hack

Pub. Number AU-B-2004257781

PCT Pub. Number WO2005/007186

Priority 60/488,263 18.07.03 US

Filing date 16 July 2004

Wipo publication date 27 January 2005

Acceptance publication date 16 July 2009

International Classifications

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

A61K 38/20 (2006.01) Medicinal preparations containing peptides - Interleukins

A61P 35/00 (2006.01) Antineoplastic agents

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/007186 Priority application(s): WO2005/007186

16 July 2009 Application Accepted

  Published as AU-B-2004257781

12 November 2009 Standard Patent Sealed

11 October 2012 Application for Amendment

  The nature of the amendment is: Amend the Patentee to read Merck Sharp & Dohme Corp. . Address for service in Australia - Griffith Hack Level 29, Northpoint 100 Miller Street North Sydney NSW 2060

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004257825-Disc brake operated pneumatically or by electric motor

2004257779-Pharmaceutical composition for inhibiting acid secretion